FERRING INT CENTER SA has a total of 50 patent applications. It decreased the IP activity by 71.0%. Its first patent ever was published in 2002. It filed its patents most often in Australia, Japan and Jordan. Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are TRIFOILIUM APS, AZTHERAPIES INC and YUYU PHARMA INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 13 | |
#2 | Japan | 12 | |
#3 | Jordan | 6 | |
#4 | Russian Federation | 3 | |
#5 | Saudi Arabia | 3 | |
#6 | United States | 3 | |
#7 | Hong Kong | 2 | |
#8 | Israel | 2 | |
#9 | South Africa | 2 | |
#10 | Brazil | 1 | |
#11 | Canada | 1 | |
#12 | Mexico | 1 | |
#13 | Norway | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Foods and drinks | |
#4 | Medical technology | |
#5 | Chemical engineering | |
#6 | Machines |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Enzymes | |
#5 | Syringes | |
#6 | Fermentation | |
#7 | Microorganisms | |
#8 | Implantable devices | |
#9 | Mixing | |
#10 | Unspecified technologies |
# | Name | Total Patents |
---|---|---|
#1 | Cottingham Ian | 12 |
#2 | White Richard Boyd | 12 |
#3 | Plaksin Daniel | 10 |
#4 | Bo-Eric Persson | 7 |
#5 | Xu Haijun | 5 |
#6 | Persson Bo-Eric | 5 |
#7 | Daniel Plaksin | 5 |
#8 | Diao Tiejun | 5 |
#9 | Ian Cottingham | 5 |
#10 | Richard Boyd White | 5 |
Publication | Filing date | Title |
---|---|---|
AU2014203174A1 | Method of treating prostate cancer with the gnrh antagonist degarelix | |
AU2013204452A1 | Process for the manufacure of a pharmaceutical product comprising citric acid, magnesium oxide, potassium bicarbonate and sodium picosulfate, pharmaceutical composition comprising granules obtained by such process and intermediate | |
JO3497B1 | Pharmaceutical preparation comprising recombinant hcg | |
JO3550B1 | Composition for the Treatment of Prostate Cancer | |
JOP20200039A1 | Pharmaceutical preparation comprising recombinant hcg | |
JO3808B1 | Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation | |
JO3525B1 | Treatment of metastatic stage prostate cancer with degarelix | |
SA2921B1 | Medicament for the Treatment of Endometriosis |